Journal Article
. 2021 Jul; 13(12):.
doi: 10.3390/cancers13123084.

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

Raquel Delgado 1 Karoline Kielbassa 1 Johanna Ter Burg 1 Christian Klein 2 Christine Trumpfheller 2 Koen de Heer 3 Arnon P Kater 4 Eric Eldering 1 
Affiliations
  • PMID: 34205588
  •     48 References

Abstract

Objectives: Chronic lymphocytic leukemia (CLL) is a common form of leukemia with a heterogeneous clinical course that remains incurable due to the development of therapy resistance. In lymph node proliferation centers, signals from the microenvironment such as CD40 ligation through interaction with follicular T helper cells shield CLL cells from apoptosis. Previous observations have shown that, despite CD40-induced changes in apoptotic mediators resulting in cell survival, CD40 activation also increases sensitivity to cell death by CD20 mAbs rituximab and obinutuzumab. To further investigate these observations, we here studied the activity of the fully human agonistic CD40 mAb selicrelumab in primary CLL cells in relation to cell activation, induced pro-survival profile, and sensitization for cell death by aCD20 mAbs, in vitro.

Methods: CLL cells from peripheral blood were isolated by the Ficoll density method. The expression of activation markers and cytokine production following CD40 stimulation was quantified by flow cytometry and ELISA. The anti-apoptotic profile of CLL induced by stimulation was evaluated by the expression of BCL-2 proteins with Western blot, and resistance to venetoclax with flow cytometry. Cell death induced by the combination of selicrelumab and aCD20 mAbs was quantified by flow cytometry.

Results: CLL cells treated with selicrelumab upregulated co-stimulatory molecules such as CD86, TNF-α and death receptor CD95/Fas. In contrast to the CD40 ligand-transfected NIH3T3 cells, induction of resistance to venetoclax by selicrelumab was very moderate. Importantly, selicrelumab stimulation positively sensitized CLL cells to CD20-induced cell death, comparable to CD40 ligand-transfected NIH3T3 cells.

Conclusions: Taken together, these novel insights into selicrelumab-stimulatory effects in CLL may be considered for developing new therapeutic strategies, particularly in combination with obinutuzumab.

Keywords: CD40 activation; CLL; aCD20 immunotherapy; venetoclax.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Andrew W Roberts, Matthew S Davids, +16 authors, John F Seymour.
N Engl J Med, 2015 Dec 08; 374(4). PMID: 26639348    Free PMC article.
Highly Cited.
A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas.
Lan V Pham, Archito T Tamayo, +4 authors, Richard J Ford.
Immunity, 2002 Feb 05; 16(1). PMID: 11825564
Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Richard S Kornbluth, Mariusz Stempniak, Geoffrey W Stone.
Int Rev Immunol, 2012 Jul 19; 31(4). PMID: 22804572    Free PMC article.
Review.
Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
Ciara L Freeman, Franck Morschhauser, +9 authors, Guillaume Cartron.
Blood, 2015 Oct 09; 126(24). PMID: 26447188    Free PMC article.
Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
J M Tromp, S H Tonino, +6 authors, E Eldering.
Oncogene, 2010 Jun 29; 29(36). PMID: 20581863
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Rachel Thijssen, Erik Slinger, +5 authors, Eric Eldering.
Haematologica, 2015 May 10; 100(8). PMID: 25957396    Free PMC article.
Predicting survival in chronic lymphocytic leukemia.
Ali Bazargan, Constantine S Tam, Michael J Keating.
Expert Rev Anticancer Ther, 2012 Mar 01; 12(3). PMID: 22369330
Review.
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Waleed Alduaij, Andrei Ivanov, +10 authors, Tim M Illidge.
Blood, 2011 Mar 08; 117(17). PMID: 21378274    Free PMC article.
Highly Cited.
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
Delfine Y H Hallaert, Annelieke Jaspers, +3 authors, Eric Eldering.
Blood, 2008 Sep 18; 112(13). PMID: 18796631
CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth.
G Pirozzi, V Lombari, +5 authors, C Manzo.
Int Immunol, 2000 Jun 06; 12(6). PMID: 10837406
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.
Richard R Furman, Andres Forero-Torres, Andrei Shustov, Jonathan G Drachman.
Leuk Lymphoma, 2009 Dec 30; 51(2). PMID: 20038235
CD40 stimulation sensitizes CLL cells to rituximab-induced cell death.
M Jak, G G W van Bochove, +2 authors, M H J van Oers.
Leukemia, 2011 Mar 16; 25(6). PMID: 21403646
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Jan A Burger, Alessandra Tedeschi, +32 authors, RESONATE-2 Investigators.
N Engl J Med, 2015 Dec 08; 373(25). PMID: 26639149    Free PMC article.
Highly Cited.
Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.
Alex Paterson, C Ian Mockridge, +6 authors, Graham Packham.
Blood, 2011 Dec 14; 119(7). PMID: 22160382
Chronic lymphocytic leukaemia.
Thomas J Kipps, Freda K Stevenson, +6 authors, Kanti Rai.
Nat Rev Dis Primers, 2017 Feb 10; 3. PMID: 28179635
CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.
Richard Batrla, Michael Linnebacher, +3 authors, Brigitte Gückel.
Cancer Res, 2002 Apr 04; 62(7). PMID: 11929824
Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.
Peter Johnson, Ruth Challis, +14 authors, Anthony Williams.
Clin Cancer Res, 2015 Jan 16; 21(6). PMID: 25589626
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Ekkehard Mössner, Peter Brünker, +22 authors, Pablo Umaña.
Blood, 2010 Mar 03; 115(22). PMID: 20194898    Free PMC article.
Highly Cited.
Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.
Wei Wen Chien, Charlène Niogret, +6 authors, Abdel Aouacheria.
Leuk Res, 2017 Jan 26; 55. PMID: 28122282
Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Lee P Richman, Robert H Vonderheide.
Cancer Immunol Res, 2014 Jan 15; 2(1). PMID: 24416732    Free PMC article.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stephan Stilgenbauer, Barbara Eichhorst, +20 authors, William G Wierda.
Lancet Oncol, 2016 May 15; 17(6). PMID: 27178240
Highly Cited.
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Ranjana Advani, Andres Forero-Torres, +6 authors, Jonathan G Drachman.
J Clin Oncol, 2009 Jul 29; 27(26). PMID: 19636010
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.
Sylvia Herter, Frank Herting, +9 authors, Christian Klein.
Haematologica, 2017 Oct 29; 103(2). PMID: 29079598    Free PMC article.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
John C Byrd, Richard R Furman, +18 authors, Susan O'Brien.
N Engl J Med, 2013 Jun 21; 369(1). PMID: 23782158    Free PMC article.
Highly Cited.
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.
Masayasu Naito, Ursula Hainz, +12 authors, Gordon J Freeman.
Cancer Immunol Immunother, 2012 Aug 29; 62(2). PMID: 22926059    Free PMC article.
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
Ann L White, Lang Dou, +14 authors, Stephen A Beers.
J Immunol, 2014 Jul 16; 193(4). PMID: 25024386
Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors.
Jennifer Q Zhang, Shan Zeng, +13 authors, Ronald P DeMatteo.
Cancer Immunol Res, 2018 Feb 23; 6(4). PMID: 29467128    Free PMC article.
Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Valentin Goede, Christian Klein, Stephan Stilgenbauer.
Oncol Res Treat, 2015 Apr 17; 38(4). PMID: 25877943
Review.
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax.
Jamie L Szocinski, Annette R Khaled, +9 authors, William J Murphy.
Blood, 2002 Jun 19; 100(1). PMID: 12070030
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Robert H Vonderheide, Keith T Flaherty, +12 authors, Scott J Antonia.
J Clin Oncol, 2007 Mar 01; 25(7). PMID: 17327609
Highly Cited.
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Manisha Singh, Christina Vianden, +15 authors, Willem W Overwijk.
Nat Commun, 2017 Nov 14; 8(1). PMID: 29129918    Free PMC article.
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Rony Dahan, Bryan C Barnhart, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2016 Jun 07; 29(6). PMID: 27265505    Free PMC article.
Highly Cited.
Agonistic CD40 antibodies and cancer therapy.
Robert H Vonderheide, Martin J Glennie.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460534    Free PMC article.
Highly Cited.
Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Yannick Le Bris, Stéphanie Struski, +7 authors, Loïc Ysebaert.
Hematol Oncol, 2016 Sep 30; 35(4). PMID: 27678008
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.
John C Byrd, Thomas J Kipps, +8 authors, Susan O'Brien.
Leuk Lymphoma, 2012 Apr 06; 53(11). PMID: 22475052    Free PMC article.
Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.
M H A van Attekum, S Terpstra, +5 authors, E Eldering.
Oncogene, 2017 Feb 14; 36(26). PMID: 28192408    Free PMC article.
CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways.
Nathalie Voorzanger-Rousselot, Laurent Alberti, Jean-Yves Blay.
BMC Cancer, 2006 Mar 21; 6. PMID: 16545138    Free PMC article.
Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation.
Wendelina J M Mackus, Susanne M A Lens, +5 authors, Eric Eldering.
Int Immunol, 2002 Aug 31; 14(9). PMID: 12202395
CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation.
Yukana Nakaima, Ken Watanabe, +2 authors, Tetsuya Fukuda.
PLoS One, 2013 May 23; 8(5). PMID: 23696891    Free PMC article.
Molecular mechanism and function of CD40/CD40L engagement in the immune system.
Raul Elgueta, Micah J Benson, +3 authors, Randolph J Noelle.
Immunol Rev, 2009 May 12; 229(1). PMID: 19426221    Free PMC article.
Highly Cited. Review.
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.
Margot Jak, Gregor G W van Bochove, +7 authors, Eric Eldering.
Blood, 2011 Sep 29; 118(19). PMID: 21948297
Anti-CD20 antibody therapy for B-cell lymphomas.
David G Maloney.
N Engl J Med, 2012 May 25; 366(21). PMID: 22621628
Highly Cited. Review.
TRAF proteins in CD40 signaling.
Gail A Bishop, Carissa R Moore, +2 authors, Zachary J Kraus.
Adv Exp Med Biol, 2007 Jul 18; 597. PMID: 17633023
Review.
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
E J Cheadle, G Lipowska-Bhalla, +4 authors, T M Illidge.
Leukemia, 2016 Nov 29; 31(7). PMID: 27890931    Free PMC article.
Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells.
Simon Latour, Marion Zanese, +8 authors, Laurence Bresson-Bepoldin.
Cancers (Basel), 2019 Mar 06; 11(3). PMID: 30832225    Free PMC article.
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Arnon P Kater, Frank Dicker, +7 authors, Thomas J Kipps.
Blood, 2005 May 26; 106(5). PMID: 15914559    Free PMC article.
Long-term human B cell lines dependent on interleukin-4 and antibody to CD40.
J Banchereau, P de Paoli, +2 authors, F Rousset.
Science, 1991 Jan 04; 251(4989). PMID: 1702555
Highly Cited.
Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4.
R Castillo, J Mascarenhas, +3 authors, E J Schattner.
Leukemia, 2000 Feb 16; 14(2). PMID: 10673747